Walleye Capital LLC Takes $2.42 Million Position in The Oncology Institute, Inc. $TOI

Walleye Capital LLC acquired a new position in shares of The Oncology Institute, Inc. (NASDAQ:TOI) in the second quarter, Holdings Channel reports. The fund acquired 445,832 shares of the company’s stock, valued at approximately $2,421,000.

Several other institutional investors have also made changes to their positions in the business. LPL Financial LLC increased its stake in Oncology Institute by 1.5% in the fourth quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock valued at $964,000 after acquiring an additional 3,900 shares during the period. AQR Capital Management LLC raised its position in Oncology Institute by 9.1% in the fourth quarter. AQR Capital Management LLC now owns 48,072 shares of the company’s stock worth $171,000 after purchasing an additional 4,007 shares in the last quarter. HighTower Advisors LLC lifted its stake in Oncology Institute by 5.5% during the fourth quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock worth $306,000 after purchasing an additional 4,489 shares during the period. Cetera Investment Advisers lifted its stake in Oncology Institute by 35.0% during the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares during the period. Finally, R Squared Ltd boosted its holdings in Oncology Institute by 42.7% during the first quarter. R Squared Ltd now owns 16,353 shares of the company’s stock valued at $50,000 after purchasing an additional 4,891 shares in the last quarter. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Stock Up 1.1%

Shares of Oncology Institute stock opened at $5.19 on Friday. The stock has a market capitalization of $512.58 million, a P/E ratio of -14.02 and a beta of 0.39. The company has a 50-day simple moving average of $5.29 and a 200 day simple moving average of $4.03. The Oncology Institute, Inc. has a 12-month low of $2.32 and a 12-month high of $6.67.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $161.28 million for the quarter, compared to analysts’ expectations of $155.28 million. On average, equities analysts anticipate that The Oncology Institute, Inc. will post -0.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TOI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research note on Friday, July 17th. BTIG Research increased their target price on Oncology Institute from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Needham & Company LLC raised their target price on Oncology Institute from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Finally, Lake Street Capital assumed coverage on Oncology Institute in a research note on Monday, July 6th. They issued a “buy” rating and a $10.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Insider Activity at Oncology Institute

In other news, insider Yale Podnos sold 23,451 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the sale, the insider owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. This trade represents a 8.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 18,000 shares of Oncology Institute stock in a transaction dated Tuesday, July 21st. The stock was acquired at an average cost of $5.27 per share, for a total transaction of $94,860.00. Following the completion of the acquisition, the insider directly owned 10,648,858 shares in the company, valued at $56,119,481.66. This represents a 0.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 131,500 shares of company stock valued at $609,265. Company insiders own 4.40% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.